Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology

Neurobiology of Aging

Volumn 35, Issue 6, 2014, Pages 1233-1242

  Orr, Miranda E ^a   Salinas, Angelica ^a   Buffenstein, Rochelle ^a   Oddo, Salvatore ^a,b,c  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Amyloid ; APP; Diabetes; Insulin resistance; Tangles; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; PEROXIDASE; TAU PROTEIN; CYCLIN DEPENDENT KINASE 5; RAPAMYCIN; SUGAR INTAKE; TARGET OF RAPAMYCIN KINASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENERGY METABOLISM; ENZYME ACTIVITY; FEMALE; HOMEOSTASIS; IMMUNOREACTIVITY; INSULIN RESISTANCE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RELATIVE DENSITY; SIGNAL TRANSDUCTION; SUGAR INTAKE; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; DIABETES MELLITUS; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CYCLIN-DEPENDENT KINASE 5; DIABETES MELLITUS; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; FEMALE; INSULIN; INSULIN RESISTANCE; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SIROLIMUS; TAU PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84903362402     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.12.006     Document Type: Article

References (61)

1. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103:26-35.
2. Backer J.M., Myers M.G., Shoelson S.E., Chin D.J., Sun X.J., Miralpeix M., Hu P., Margolis B., Skolnik E.Y., Schlessinger J., White M.F. Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 1992, 11:3469-3479.
3. Becker K., Freude S., Zemva J., Stohr O., Krone W., Schubert M. Chronic peripheral hyperinsulinemia has no substantial influence on tau phosphorylation invivo. Neurosci. Lett. 2012, 516:306-310.
4. Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006, 5:64-74.
5. Binder L.I., Guillozet-Bongaarts A.L., Garcia-Sierra F., Berry R.W. Tau, tangles, and Alzheimer's disease. Biochim. Biophys. Acta 2005, 1739:216-223.
6. Bitel C.L., Kasinathan C., Kaswala R.H., Klein W.L., Frederikse P.H. Amyloid-beta and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J.Alzheimers Dis. 2012, 32:291-305.
7. Caccamo A., Magri A., Medina D.X., Wisely E.V., Lopez-Aranda M.F., Silva A.J., Oddo S. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell 2013, 12:370-380.
8. Caccamo A., Majumder S., Richardson A., Strong R., Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and tau: effects on cognitive impairments. J.Biol. Chem. 2010, 285:13107-13120.
9. Caccamo A., Maldonado M.A., Majumder S., Medina D.X., Holbein W., Magri A., Oddo S. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J.Biol. Chem. 2011, 286:8924-8932.
10. Cao D., Lu H., Lewis T.L., Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J.Biol. Chem. 2007, 282:36275-36282.
11. Cavallini A., Brewerton S., Bell A., Sargent S., Glover S., Hardy C., Moore R., Calley J., Ramachandran D., Poidinger M., Karran E., Davies P., Hutton M., Szekeres P., Bose S. An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J.Biol. Chem. 2013, 288:23331-23347.
12. Cholerton B., Baker L.D., Craft S. Insulin, cognition, and dementia. Eur. J. Pharmacol. 2013, 719:170-179.
13. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U.S.A 2008, 105:17414-17419.
14. Copps K.D., White M.F. Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia 2012, 55:2565-2582.
15. Cortes C.J., Qin K., Cook J., Solanki A., Mastrianni J.A. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann-Straussler-Scheinker disease. J.Neurosci. 2012, 32:12396-12405.
16. Devi L., Alldred M.J., Ginsberg S.D., Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of beta-amyloidosis in a mouse model of Alzheimer's disease. PLoS One 2012, 7:e32792.
17. Fang Y., Westbrook R., Hill C., Boparai R.K., Arum O., Spong A., Wang F., Javors M.A., Chen J., Sun L.Y., Bartke A. Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab. 2013, 17:456-462.
18. 2. J.Neurochem. 2013, 126:234-242.
19. Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., Pahor M., Javors M.A., Fernandez E., Miller R.A. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009, 460:392-395.
20. Jimenez-Palomares M., Ramos-Rodriguez J.J., Lopez-Acosta J.F., Pacheco-Herrero M., Lechuga-Sancho A.M., Perdomo G., Garcia-Alloza M., Cozar-Castellano I. Increased abeta production prompts the onset of glucose intolerance and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2012, 302:E1373-E1380.
21. Jolivalt C.G., Hurford R., Lee C.A., Dumaop W., Rockenstein E., Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp. Neurol. 2010, 223:422-431.
22. Jolivalt C.G., Lee C.A., Beiswenger K.K., Smith J.L., Orlov M., Torrance M.A., Masliah E. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J.Neurosci. Res. 2008, 86:3265-3274.
23. Jones A., Kulozik P., Ostertag A., Herzig S. Common pathological processes and transcriptional pathways in Alzheimer's disease and type 2 diabetes. J.Alzheimers Dis. 2009, 16:787-808.
24. Ke Y.D., Delerue F., Gladbach A., Gotz J., Ittner L.M. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 2009, 4:e7917.
25. Lamming D.W., Sabatini D.M. Acentral role for mTOR in lipid homeostasis. Cell Metab. 2013, 18:465-469.
26. Lamming D.W., Ye L., Astle C.M., Baur J.A., Sabatini D.M., Harrison D.E. Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive. Aging Cell 2013, 12:712-718.
27. Lamming D.W., Ye L., Katajisto P., Goncalves M.D., Saitoh M., Stevens D.M., Davis J.G., Salmon A.B., Richardson A., Ahima R.S., Guertin D.A., Sabatini D.M., Baur J.A. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012, 335:1638-1643.
28. Lew J., Huang Q.Q., Qi Z., Winkfein R.J., Aebersold R., Hunt T., Wang J.H. Abrain-specific activator of cyclin-dependent kinase 5. Nature 1994, 371:423-426.
29. Liu Y., Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J.Neurochem. 2009, 111:242-249.
30. Majumder S., Caccamo A., Medina D.X., Benavides A.D., Javors M.A., Kraig E., Strong R., Richardson A., Oddo S. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell 2012, 11:326-335.
31. Majumder S., Richardson A., Strong R., Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 2011, 6:e25416.
32. Mannaa M., Kramer S., Boschmann M., Gollasch M. mTOR and regulation of energy homeostasis in humans. J.Mol. Med. (Berl) 2013, 91:1167-1175.
33. Martin L., Latypova X., Wilson C.M., Magnaudeix A., Perrin M.L., Yardin C., Terro F. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 2013, 12:289-309.
34. Mayeux R., Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect. Med. 2012, 2.
35. Medina D.X., Caccamo A., Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011, 21:140-149.
36. Myers M.G., Backer J.M., Sun X.J., Shoelson S., Hu P., Schlessinger J., Yoakim M., Schaffhausen B., White M.F. IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85. Proc. Natl. Acad. Sci. U.S.A 1992, 89:10350-10354.
37. Oddo S. The role of mTOR signaling in Alzheimer disease. Front Biosci. (Schol Ed.) 2012, 4:941-952.
38. Oddo S., Caccamo A., Cheng D., Jouleh B., Torp R., LaFerla F.M. Genetically augmenting tau levels does not modulate the onset or progression of abeta pathology in transgenic mice. J.Neurochem. 2007, 102:1053-1063.
39. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
40. Oddo S., Caccamo A., Tseng B., Cheng D., Vasilevko V., Cribbs D.H., LaFerla F.M. Blocking abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between abeta and tau pathology. J.Neurosci. 2008, 28:12163-12175.
41. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
42. Pei J.J., Hugon J. mTOR-dependent signalling in Alzheimer's disease. J.Cell. Mol. Med. 2008, 12:2525-2532.
43. Plaschke K., Kopitz J., Siegelin M., Schliebs R., Salkovic-Petrisic M., Riederer P., Hoyer S. Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 abetaPP-overexpressing mice. J.Alzheimers Dis. 2010, 19:691-704.
44. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
45. Rivera E.J., Goldin A., Fulmer N., Tavares R., Wands J.R., de la Monte S.M. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J.Alzheimers Dis. 2005, 8:247-268.
46. Saha A.K., Xu X.J., Balon T.W., Brandon A., Kraegen E.W., Ruderman N.B. Insulin resistance due to nutrient excess: is it a consequence of AMPK downregulation?. Cell Cycle 2011, 10:3447-3451.
47. Sims-Robinson C., Kim B., Rosko A., Feldman E.L. How does diabetes accelerate Alzheimer disease pathology?. Nat. Rev. Neurol. 2010, 6:551-559.
48. Spilman P., Podlutskaya N., Hart M.J., Debnath J., Gorostiza O., Bredesen D., Richardson A., Strong R., Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010, 5:e9979.
49. Stambolic V., Woodgett J.R. Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 1994, 303(Pt 3):701-704.
50. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., Xu X.J., Wands J.R., de la Monte S.M. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J.Alzheimers Dis. 2005, 7:63-80.
51. Takeda S., Sato N., Uchio-Yamada K., Sawada K., Kunieda T., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., Morishita R. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U.S.A 2010, 107:7036-7041.
52. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J.Clin. Invest. 2012, 122:1316-1338.
53. Tang D., Yeung J., Lee K.Y., Matsushita M., Matsui H., Tomizawa K., Hatase O., Wang J.H. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J.Biol. Chem. 1995, 270:26897-26903.
54. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9:753-762.
55. Tsai L.H., Delalle I., Caviness V.S., Chae T., Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994, 371:419-423.
56. Ubeda M., Kemp D.M., Habener J.F. Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells. Endocrinology 2004, 145:3023-3031.
57. Utreras E., Terse A., Keller J., Iadarola M.J., Kulkarni A.B. Resveratrol inhibits Cdk5 activity through regulation of p35 expression. Mol. Pain 2011, 7:49.
58. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
59. Ye Y., Xie H., Zhao X., Zhang S. The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diagnostic test accuracy. Cardiovasc. Diabetol. 2012, 11:155.
60. Zhang H.H., Huang J., Duvel K., Boback B., Wu S., Squillace R.M., Wu C.L., Manning B.D. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One 2009, 4:e6189.
61. Zhu W.L., Shi H.S., Wang S.J., Xu C.M., Jiang W.G., Wang X., Wu P., Li Q.Q., Ding Z.B., Lu L. Increased Cdk5/p35 activity in the dentate gyrus mediates depressive-like behaviour in rats. The Int. J. Neuropsychopharmacol. 2012, 15:795-809.